Motor Neurone Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with amyotrophic lateral sclerosis (ALS), either as a possible, probable, or confirmed diagnosis, based on recognised medical criteria
- People whose first ALS symptoms (muscle weakness or speech/swallowing problems) began less than 24 months ago
- People whose ALS has been progressing at a certain minimum rate, measured using a standard ALS function score (confirm with trial site for the exact calculation)
- People aged 18 years or older
- People who have either been on a stable, consistent dose of riluzole, or have not taken riluzole for at least 4 weeks before joining
- People who have either been on a stable, consistent dose of edaravone, or have not taken edaravone for at least 4 weeks before joining
- People who have either been on a stable, consistent dose of sodium-phenylbutyrate/taurursodiol, or have not taken this medication for at least 4 weeks before joining
- People who are able to fully understand all information provided about the trial and give written consent to participate
Who may not be able to join:
- People who have taken part in another clinical trial involving an active treatment within the past 4 weeks
- People who have had a tracheostomy or who depend on a ventilator for more than 22 hours per day
- People who are pregnant or breastfeeding
- People who have another medical condition affecting the motor nerves that could make it difficult to confirm an ALS diagnosis
- People who have another serious or life-threatening illness that could affect the ability to assess their physical function
- People who have a significant psychiatric condition or notable cognitive decline that would make it difficult to assess their symptoms
- People who, in the opinion of the trial investigator, are unlikely to be able to cooperate with or follow study requirements, or who cannot be contacted in an emergency
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Johannes Dorst, Prof. Dr., University of Ulm
Phone: +497311775285
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.